Barré for every million doses given.
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
1d
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.
The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...
Berenberg Bank analyst Kerry Holford maintained a Hold rating on FRESNILLO (FNLPF – Research Report) yesterday and set a price target of ...
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback